Success Metrics

Clinical Success Rate

100.0%

Based on 8 completed trials

Completion Rate

100%(8/8)

Active Trials

0(0%)

Results Posted

88%(7 trials)

Phase Distribution

Ph phase_2

38%

Ph phase_3

50%

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

4(50.0%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 23 (37.5%)

Phase 34 (50.0%)

Phase 41 (12.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

NCT00463437

completedphase_2

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

NCT00127855

completedphase_2

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

NCT00129116

completedphase_3

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

NCT00586612

completedphase_2

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

NCT00134719

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT00463437Phase 3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Completed

NCT00127855Phase 2

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Completed

NCT00129116Phase 2

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Completed

NCT00586612Phase 3

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Completed

NCT00134719Phase 2

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Completed

NCT00611559Phase 4

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

Completed

NCT00322335Phase 3

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Completed

NCT00327184Phase 3

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Completed

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8